The Tasmanian Government is delivering a life-saving meningococcal B vaccination program, providing free protection for all Tasmanian infants against the disease.
Premier Jeremy Rockliff said meningococcal disease is a rare but serious illness that can quickly become life threatening.
“Meningococcal disease can affect people at any age, but it is most common in infants, young children and adolescents,” the Premier said.
“Vaccination is the best protection we have against this devastating disease, which is why we’re delivering this program to ensure every Tasmanian infant can access this life-saving vaccine.
“Through our 2030 Strong Plan for Tasmania’s Future, we are delivering important healthcare initiatives for families and tackling the cost of living.”
Minister for Health, Mental Health and Wellbeing, Bridget Archer, said the Government is delivering free meningococcal B vaccinations for all infants from six weeks of age to up to two years, as well as catch-up vaccination for children born from 1 July 2025.
“We know cost has been a barrier for many families, with the vaccine previously only available through private prescription,” Minister Archer said.
“Our $4 million investment removes that barrier, ensuring every Tasmanian infant can receive this important protection at no cost.”
The meningococcal B vaccine for Tasmanian infants is now available through general practices and some local council clinics.
Under the National Immunisation Program, meningococcal B vaccination is funded for Aboriginal and Torres Strait Islander infants and people of any age with medical conditions that increase their risk.
People with meningococcal disease often go from feeling well to extremely unwell very quickly. Symptoms of meningococcal disease can include rash, severe headache, fever, confusion and muscle pain.
Babies and infants may not have these symptoms but can be unsettled or drowsy, floppy, and not feed.
Meningococcal ACWY vaccine remains recommended and free through the National Immunisation Program for children aged 12 months, and for adolescents aged 14 to 19 years.
Meningococcal ACWY and B vaccines continue to be recommended and available privately for other people who are not covered by funded programs but would like to protect themselves against the disease.
